STM JOURNALS

Research & Reviews: Journal of
Dairy Science & Technology

https://journals.stmjournals.com/rrjodst

ISSN: 2319-3409 (Online)
ISSN: 2349-3704 (Print)
Volume 13, Issue 2, 2024
May–August
DOI (Journal): 10.37591/RRJoDST

Research RRJoDST

Bacteriophage Therapy in Dairy Farming: A Potential Alternative to Antibiotics

Swati Sharma[1,*]

Abstract

The widespread use of antibiotics in dairy farming to control bacterial infections has led to significant challenges, including the emergence of antibiotic-resistant bacteria and concerns over antibiotic residues in milk. Consequently, there is an increasing demand for alternative approaches to control bacterial infections in dairy cattle. One promising solution is bacteriophage therapy, which uses viruses that selectively infect and destroy bacteria. As a result, the need for new strategies to manage bacterial infections in dairy cattle is rising. Bacteriophage therapy, which involves viruses that specifically target and eliminate bacteria, offers a promising alternative. Bacteriophages, or phages, have a unique mechanism of action that allows them to selectively infect and lyse bacterial cells, making them highly specific to their target bacteria. This targeted approach minimizes the disruption of beneficial microbial communities and reduces the likelihood of developing resistance, unlike broad-spectrum antibiotics. Historically, bacteriophage therapy was overshadowed by the advent of antibiotics, but recent advancements and the rise of antibiotic resistance have renewed interest in this approach. The application of phage therapy in dairy farming has shown success in controlling infections such as mastitis, a prevalent and costly disease in dairy cows caused by pathogenic bacteria. Field trials and case studies demonstrate that phage therapy can effectively reduce bacterial loads, improve animal health, and enhance milk quality. Additionally, phages provide the benefit of being environmentally friendly and suitable for organic farming practices. Despite its potential, bacteriophage therapy faces challenges, including regulatory hurdles, phage resistance, and the need for efficient delivery systems. Advances in phage formulation, the use of phage cocktails, and genetic engineering are being explored to overcome these limitations. Furthermore, the regulatory landscape needs to adapt to accommodate phage therapy, ensuring safety and efficacy standards are met.

Keywords: Dairy farming, bacteriophages, antibiotics, ethical considerations, *Escherichia coli, Staphylococcus aureus*

INTRODUCTION

Bacterial infections in dairy farms are a significant concern, affecting both animal health and milk production. Common infections, such as mastitis, caused by bacteria such as *Staphylococcus aureus* and *Escherichia coli*, lead to decreased milk yield, poor milk quality, and substantial economic losses. To manage these infections, dairy farmers traditionally rely heavily on antibiotics. Although effective, this approach has led to several critical issues, notably the emergence of antibiotic-resistant bacteria [1]. The overuse and misuse of antibiotics in agriculture contribute to this global health crisis, making infections harder to treat and posing a threat to both animal and human health. Additionally, antibiotic residues in milk raise safety concerns for consumers and complicate the processing of milk.

In response to these challenges, there is growing interest in alternative methods for controlling

***Author for Correspondence**
Swati Sharma
E-mail: swati.sharma7834@gmail.com

[1]Technician, Multi-disciplinary Reteach unit, University College of Medical Sciences & GTB Hospital, Delhi, India

Received Date: July 21, 2024
Accepted Date: August 02, 2024
Published Date: August 20, 2024

Citation: Swati Sharma. Bacteriophage Therapy in Dairy Farming: A Potential Alternative to Antibiotics. Research & Reviews: Journal of Dairy Science & Technology. 2024; 13(2): 1–5p.

© STM Journals 2024. All Rights Reserved

bacterial infections in dairy farming. Bacteriophage therapy, which uses viruses that specifically infect and kill bacteria, is a promising solution. Bacteriophages or phages are highly specific to their bacterial hosts, meaning they can target and eradicate pathogenic bacteria without harming beneficial microbes or the host animal [2]. Moreover, phages are natural entities found ubiquitously in the environment and have a long history of safe use in treating bacterial infections before the advent of antibiotics. As antibiotic resistance continues to increase, bacteriophage therapy is gaining renewed attention as a viable and sustainable alternative for managing bacterial infections in dairy farming [3].

BACTERIOPHAGES: NATURE AND MECHANISM OF ACTION

Bacteriophages, often known as phages, are viruses that target and destroy bacterial cells. They are the most abundant biological entities on Earth and are found in diverse environments such as soil, water, and various organisms. There are several types of bacteriophages classified based on their morphology and genetic material, including tailed phages (order Caudovirales), filamentous phages, and others with complex structures. The two primary types of phage lifecycle are lytic and lysogenic.

During the lytic cycle, a phage binds to a bacterial cell, inserts its genetic material, and takes over bacterial machinery to produce new phage particles. This leads to lysis of bacterial cells, releasing new phages to infect additional bacteria. In contrast, the lysogenic cycle involves integrating the genetic material of the phage into the bacterial genome, allowing it to remain dormant for long periods. Under specific conditions, the prophage can become activated, transitioning to the lytic cycle and starting the production of new phages. Bacteriophages target and kill bacteria via highly specific and effective mechanisms. Phages recognize and bind to specific receptors on the surface of bacterial cells, which determine their host range. Once a phage attaches, it injects DNA or RNA into the host cell. During the lytic cycle, the phage genome commands the bacterial machinery to replicate its components, assemble new phage particles, and produce enzymes that break down the bacterial cell wall, resulting in cell lysis and release of new phages [4].

HISTORICAL CONTEXT OF BACTERIOPHAGE THERAPY

Bacteriophage therapy has a rich history dating back to the early 20th century. The discovery of bacteriophages was credited to Frederick Twort in 1915 and Félix d'Hérelle in 1917, who independently identified viruses capable of infecting and lysing bacteria [5]. Soon after their discovery, phages were used to treat bacterial infections in humans and animals, showing promising results in medicine and agriculture. Phage therapy gained popularity in the 1920s and the 1930s, with successful treatment reported for diseases such as dysentery, cholera, and wound infections. Agricultural applications include the use of phages to control bacterial pathogens in livestock and other crops. However, the advent of antibiotics in the 1940s, with their broad-spectrum efficacy and ease of production, has led to a significant decline in the use of phage therapy. Antibiotics are more convenient and reliable, overshadowing the more complex and less-understood phage treatments [6]. Consequently, research and development in phage therapy have diminished, particularly in Western countries. Nonetheless, phage therapy has been used and studied in Eastern Europe and the former Soviet Union, where antibiotics are less accessible.

APPLICATION OF BACTERIOPHAGE THERAPY IN DAIRY FARMING

In dairy farming, bacterial infections pose significant challenges, affecting the health of dairy cows and milk quality. One of the most prevalent and costly infections is mastitis, an inflammation of the udder typically caused by bacteria such as *Staphylococcus aureus*, *Escherichia coli*, and *Streptococcus uberis*. Mastitis leads to decreased milk yield, altered milk composition, and increased somatic cell counts, all of which affect milk quality and farmers' income. Traditional antibiotic treatments have limitations, including the development of antibiotic resistance, withdrawal periods to avoid antibiotic residues in milk, and disruption of the beneficial microbiota. Bacteriophage therapy has emerged as a promising alternative for the control of bacterial infections in dairy cows. Specific phages can be isolated and tailored to target pathogens that cause infections, such as mastitis. For example, phages

© STM Journals 2024. All Rights Reserved

targeting *Staphylococcus aureus* have been successfully used to reduce bacterial loads and improve udder health. These phages act by infecting and lysing pathogenic bacteria, effectively reducing infection severity without harming beneficial bacteria or leaving harmful residues in milk [7]. Numerous case studies and field trials have demonstrated the efficacy of bacteriophage therapy in dairy farms. In one study, a bacteriophage preparation was applied to cows with clinical mastitis, resulting in significant reductions in bacterial counts and clinical symptoms. Another field trial involved the use of phage-based teat disinfectants, which effectively prevented new infections during the dry period and reduced the incidence of mastitis during subsequent lactation. These examples highlight the potential of phage therapy not only for treating active infections but also for preventing the occurrence of new infections, thereby promoting better overall herd health [8].

ADVANTAGES OF BACTERIOPHAGE THERAPY OVER ANTIBIOTICS

Bacteriophage therapy offers several advantages over traditional antibiotics, particularly in dairy farming. One of the most significant benefits is the target specificity of bacteriophages. Unlike broad-spectrum antibiotics that indiscriminately kill harmful and beneficial bacteria, phages are highly specific to their bacterial hosts. This specificity allows phages to precisely target pathogenic bacteria causing infections such as mastitis, without disrupting the beneficial microbiota essential for cow health. This targeted approach reduces collateral damage and supports the overall microbiome balance in dairy cows [9, 10].

REGULATORY AND ETHICAL CONSIDERATIONS

The integration of bacteriophage therapy into agricultural practices, including dairy farming, necessitates careful consideration of the regulatory and ethical aspects.

- The current regulatory frameworks for phage therapy in agriculture vary significantly by region. The regulatory landscape for phage therapy is still under development in many countries. In Europe, the European Food Safety Authority (EFSA) and various national agencies regulate the use of phages, often requiring rigorous safety and efficacy assessments before approval. These regulations typically involve comprehensive studies to demonstrate that phage products are safe for both animals and humans, do not negatively affect the environment, and do not lead to the development of resistance. As the application of phage therapy in agriculture expands, there is a growing need for standardized regulatory frameworks that ensure consistency and address the emerging challenges associated with phage use [11].
- Ethical considerations regarding the use of bacteriophages in food-producing animals play a crucial role. Introducing phages into the environment or animal systems can disrupt existing microbial communities, potentially leading to unforeseen consequences. Therefore, ethical considerations must include thorough risk assessment and monitoring to mitigate adverse effects. Transparency in the development and application of phage therapy is vital for maintaining public trust. Consumers and farmers require clear information about the safety, efficacy, and regulatory status of phage products.[12].
- Moreover, there are ethical questions regarding animal welfare and the use of biotechnological interventions. Ensuring that phage therapy is used as part of a broader strategy to improve animal health and reduce reliance on antibiotics aligns with the ethical principles of minimizing harm and promoting sustainable practices. Effectively navigating the ethical landscape of phage therapy requires continuous discussion among scientists, regulators, farmers, and the public to balance its benefits with these considerations.
- Overall, the target specificity, reduced risk of antibiotic resistance, and compatibility with organic farming practices make bacteriophage therapy a promising and sustainable alternative to traditional antibiotics in dairy farming. Continued research and development are essential to fully harness these advantages and to integrate phage therapy into mainstream agricultural practices [13].

© STM Journals 2024. All Rights Reserved

TECHNOLOGICAL ADVANCES AND INNOVATIONS

The resurgence of interest in bacteriophage therapy has been accompanied by significant technological advances and innovations, which have enhanced its effectiveness and application in dairy farming. One of the key areas of development is the formulation and delivery of phage therapy. Modern techniques have enabled the creation of more stable and efficient phage formulations that can withstand the harsh conditions of the gastrointestinal tract and environment. Encapsulation technologies such as microencapsulation and nanoencapsulation protect phages from degradation and ensure their controlled release at the site of infection. Additionally, novel delivery methods, including phage-impregnated teat wipes and sprays, have been developed to facilitate the direct application of phages to infected areas, improving their efficacy in treating infections, such as mastitis.

The use of phage cocktails and phage engineering represents another significant advancement. Phage cocktails, which are mixtures of multiple phages targeting different bacterial strains or species, broaden the spectrum of bacteria that can be targeted and reduce the likelihood of resistance development. This approach ensures that a single bacterial mutation does not render therapy ineffective. Furthermore, advances in genetic engineering have enabled scientists to modify phages to enhance their antibacterial activity. Engineered phages can be tailored to target specific bacterial virulence factors or carry genes that confer additional antibacterial activities, such as enzymes that degrade biofilms, making them more potent against bacterial infections.

Integration with other biocontrol methods, such as probiotics, represents a holistic approach to managing bacterial infections in dairy farming. Combining phage therapy with probiotics can enhance the overall health and resilience of dairy cow microbiomes. Probiotics, beneficial bacteria that promote gut health, can work synergistically with phages to suppress pathogenic bacteria. This combined approach not only treats infections but also supports the cow's immune system and prevents the establishment of harmful bacteria. Such integrated biocontrol strategies are particularly appealing in organic and sustainable farming practices, where the goal is to reduce reliance on chemical treatments and maintain a balanced ecosystem.

CONCLUSION

Bacteriophage therapy is a promising alternative to traditional antibiotics in dairy farming, addressing critical challenges, such as bacterial infections, antibiotic resistance, and the need for sustainable agricultural practices. This review highlights several key points: the unique ability of phages to target and kill specific bacterial pathogens without disrupting beneficial microbes; their potential to reduce the development of antibiotic resistance; and their compatibility with organic and antibiotic-free farming practices. Advancements in phage therapy, including improved formulation and delivery methods, the use of phage cocktails, and integration with other biocontrol methods, such as probiotics, underscore the transformative potential of this approach. By enhancing the precision and effectiveness of infection management, bacteriophage therapy can significantly improve animal health and milk quality, while reducing reliance on conventional antibiotics. There is a need for continued research and development to fully realize the benefits of bacteriophage therapy. Collaborative efforts among scientists, farmers, and policymakers are crucial for addressing regulatory and ethical considerations, optimizing phage applications, and ensuring safe and effective integration of phage therapy into dairy farming practices. Such collaboration will help pave the way for a more sustainable and resilient agricultural system, ultimately benefiting both the dairy industry and public health.

REFERENCES

1. Kahn LH, Bergeron G, Bourassa MW, De Vegt B, Gill J, Gomes F, et al. From farm management to bacteriophage therapy: Strategies to reduce antibiotic use in animal agriculture. Ann N Y Acad Sci. 2019 Apr;1441(1):31-9. DOI: 10.1111/nyas.14034. PubMed: 30924542.
2. Angelopoulou A, Warda AK, Hill C, Ross RP. Non-antibiotic microbial solutions for bovine mastitis – live biotherapeutics, bacteriophage, and phage lysins. Crit Rev Microbiol. 2019;45(5-6):564-80. DOI: 10.1080/1040841X.2019.1648381. PubMed: 31403343.

© STM Journals 2024. All Rights Reserved

3. Kanwar R, Aslam MA, Zulqurnain H, Qadeer A, Ali S, Nayab S, et al. Bacteriophages and their endolysin: An alternative therapeutic approach for bovine mastitis. Biol Bull Rev. 2023;13(4):326-35. DOI: 10.1134/S2079086423040059.
4. Labrie SJ, Samson JE, Moineau S. Bacteriophage resistance mechanisms. Nat Rev Microbiol. 2010 May;8(5):317-27. DOI: 10.1038/nrmicro2315. PubMed: 20348932.
5. Britannica, the editors of encyclopaedia. Virology [Internet]. Encyclopedia Britannica; 2017 [cited 2024 Jul 21]. Available from: https://www.britannica.com/science/virology.
6. Clark JR. Bacteriophage therapy: History and future prospects. Future Virol. 2015;10(6):449-61. DOI: 10.2217/fvl.15.3.
7. Kahn LH, Bergeron G, Bourassa MW, De Vegt B, Gill J, Gomes F, et al. From farm management to bacteriophage therapy: strategies to reduce antibiotic use in animal agriculture. Ann N Y Acad Sci. 2019 Apr;1441(1):31-9. DOI: 10.1111/nyas.14034.
8. Gutiérrez D, Fernández L, Rodríguez A, García P. Role of bacteriophages in the implementation of a sustainable dairy chain. Front Microbiol. 2019;10:12. DOI: 10.3389/fmicb.2019.00012. PubMed: 30723460.
9. Golkar Z, Bagasra O, Pace DG. Bacteriophage therapy: A potential solution for the antibiotic resistance crisis. J Infect Dev Ctries. 2014;8(2):129-36. DOI: 10.3855/jidc.3573. PubMed: 24518621.
10. Loc-Carrillo C, Abedon ST. Pros and cons of phage therapy. Bacteriophage. 2011;1(2):111-4. DOI: 10.4161/bact.1.2.14590. PubMed: 22334867.
11. Verbeken G, Huys I, Pirnay JP, Jennes S, Chanishvili N, Scheres J, et al. Taking bacteriophage therapy seriously: A moral argument. Biomed Res Int. 2014;2014:621316. DOI: 10.1155/2014/621316. PubMed: 24868534.
12. Verbeken G, De Vos D, Vaneechoutte M, Merabishvili M, Zizi M, Pirnay JP. European regulatory conundrum of phage therapy. Future Microbiol. 2007;2(5):485-91. DOI: 10.2217/17460913.2.5.485. PubMed: 17927471.
13. Plaut RD, Stibitz S. Regulatory considerations for bacteriophage therapy products. Phage Ther. 2019:337-49.

© STM Journals 2024. All Rights Reserved